Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News GT Biopharma Inc GTBP

Healthcare Biotechnology Diagnostics & Research
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GTBP)

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire 12 days ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 15, 2024

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire March 26, 2024

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

GlobeNewswire February 1, 2024

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote "FOR" All Proposed Items at the Upcoming Special Meeting of Stockholders

GlobeNewswire December 6, 2023

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GlobeNewswire December 4, 2023

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GlobeNewswire November 6, 2023

GT Biopharma Reports Third Quarter 2023 Financial Results

GlobeNewswire November 1, 2023

GT Biopharma Reports Second Quarter 2023 Financial Results

GlobeNewswire August 7, 2023
View More News ››

Opinion & Analysis (NDAQ:GTBP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GTBP)

What's Going On With GT Biopharma Stock? | Benzinga

News; $GTBP What's Going On With GT Biopharma Stock? | BenzingaGT Biopharma, Inc. (NASDAQ:GTBP) shares are racing higher Monday on...
whytestocks - 12 days ago

What made GT Biopharma stock more than double on Monday?

News; $GTBP What made GT Biopharma stock more than double on Monday?2024-05-20 10:43:46 ET GT Biopharma Inc (NASDAQ: GTBP) is up a...
whytestocks - 13 days ago
View more Bullboard ››

Theralase Technologies Inc.

Theralase Technologies Inc.

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research ...
View More »